United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Friday, April 24th. The shares were sold at an average price of $564.81, for a total value of $5,365,695.00. Following the sale, the chief executive officer directly owned 40,513 shares in the company, valued at $22,882,147.53. The trade was a 19.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $566.99 on Tuesday. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $607.89. The firm has a market capitalization of $24.85 billion, a PE ratio of 20.32, a price-to-earnings-growth ratio of 1.61 and a beta of 0.75. The stock has a fifty day moving average of $538.38 and a two-hundred day moving average of $495.47.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts’ consensus estimates of $6.78 by $0.92. The business had revenue of $790.20 million for the quarter, compared to analysts’ expectations of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $6.19 earnings per share. Equities research analysts predict that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently commented on UTHR shares. Morgan Stanley raised their price objective on shares of United Therapeutics from $471.00 to $519.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. Bank of America lifted their price target on United Therapeutics from $569.00 to $626.00 and gave the company a “neutral” rating in a research report on Tuesday, March 31st. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research note on Thursday, February 26th. Finally, Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $601.50.

Institutional Trading of United Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Torren Management LLC purchased a new position in shares of United Therapeutics during the fourth quarter valued at $26,000. Activest Wealth Management lifted its stake in United Therapeutics by 1,400.0% in the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC boosted its position in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares during the period. Rakuten Securities Inc. boosted its position in United Therapeutics by 76.7% during the 2nd quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC purchased a new position in United Therapeutics during the 4th quarter valued at about $31,000. 94.08% of the stock is owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.